4523 N Stock Overview Engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Eisai Co., Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for Eisai Historical stock prices Current Share Price JP¥888.98 52 Week High JP¥1,064.45 52 Week Low JP¥888.98 Beta -0.021 1 Month Change 0% 3 Month Change n/a 1 Year Change n/a 3 Year Change -38.75% 5 Year Change n/a Change since IPO -36.25%
Recent News & Updates
Eisai Co., Ltd. and Biogen Inc. Announces Approval of ''LEQEMBI" (Lecanemab) for the Treatment of Early Alzheimer's Disease in Mexico Dec 05 Eisai Co., Ltd. and Biogen Inc. Announce "LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea Eisai Co., Ltd. and Biogen Inc. Receive Positive Opinion from CHMP in European Union for Lecanemab in Early Alzheimer’s Disease
Eisai Completes Rolling BLA Submission for Subcutaneous Maintenance Dosing of Leqembi® (lecanemab-irmb) in the US Nov 02
Eisai Co., Ltd. and Biogen Inc. Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance Dosing Nov 01
Eisai Co., Ltd. Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference Oct 31 See more updates
Eisai Co., Ltd. and Biogen Inc. Announces Approval of ''LEQEMBI" (Lecanemab) for the Treatment of Early Alzheimer's Disease in Mexico Dec 05 Eisai Co., Ltd. and Biogen Inc. Announce "LEQEMBI®" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea Eisai Co., Ltd. and Biogen Inc. Receive Positive Opinion from CHMP in European Union for Lecanemab in Early Alzheimer’s Disease
Eisai Completes Rolling BLA Submission for Subcutaneous Maintenance Dosing of Leqembi® (lecanemab-irmb) in the US Nov 02
Eisai Co., Ltd. and Biogen Inc. Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance Dosing Nov 01
Eisai Co., Ltd. Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference Oct 31 Merck and Eisai Announce Results from the First Interim Analysis of the Phase 3 LEAP-012 Trial Evaluating KEYTRUDA® (Pembrolizumab) Sep 16
Eisai Co., Ltd. Accelerates Progress in Oncology Research with New Data At Esmo Congress 2024 Sep 04
BioArctic AB (Publ) Partner Eisai Announces Leqembi (Lecanemab) Authorized for Early Alzheimer's Disease in Great Britain Aug 22
Eisai Co., Ltd. and Biogen Inc. Announces New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting Leqemab (Lecanemab-Irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at the Alzheimer's Association International Conference Jul 31 Eisai Provides Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union
Eisai Co. Ltd Announces To Present Latest Findings on Its Alzheimer's Disease Pipeline and Research Jul 23
Eisai Announces Approval for the Treatment of Alzheimer's Disease in Israel Jul 12 Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China Jun 28
Eisai Co., Ltd. (TSE:4523) announces an Equity Buyback for 6,500,000 shares, representing 2.26% for ¥30,000 million. May 17 Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status May 16
Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA Apr 02
BioArctic AB (publ) and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders Mar 14 Eisai Co., Ltd. to Report Q3, 2025 Results on Feb 07, 2025
Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa® Feb 23
Eisai Announces Leqembi Approval for the Treatment of Alzheimer's Disease in China Jan 09
Eisai Co., Ltd. Announces Launch of LEQEMBI in Japan on December 20 Dec 13 Merck and Eisai Provide Update on Phase 3 Leap-001 Trial Evaluating (Pembrolizumab) Plus Lenvima(R) (Lenvatinib) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma Dec 08
High number of new directors Nov 17 Eisai Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024
Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's Disease Oct 27
Eisai Co., Ltd., Annual General Meeting, May 22, 2024 Oct 20
NTT DOCOMO, INC completed the acquisition of 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others. Oct 18
Eisai Co., Ltd. to Present New Data from LEQEMBI Phase 3 Clarity AD Study and Other Alzheimer's Disease Pipeline Research at the Clinical Trials on Alzheimer's Disease Conference Oct 16 Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in Japan Sep 25
Eisai and Merck Provide Update on Two Phase 3 Trials Evaluating Lenvima Plus Keytruda with Certain Types of Metastatic Non-Small Cell Lung Cancer Sep 23
NTT DOCOMO, INC made a tender offer to acquire 51% stake in INTAGE HOLDINGS Inc. (TSE:4326) from Eisai Co., Ltd., Saitama Resona Bank, Ltd., Daiei Real Estate & Development Co., Ltd, Mizuho Bank, Ltd., MUFG Bank, Ltd., Shutoken Leasing Co, Ltd. and others for ¥47 billion. Sep 08 Merck and Eisai Provides Update on Phase 3 Leap-010 Trial Evaluating Keytruda (Pembrolizumab) Plus Lenvima (Lenvatinib) in Patients with Certain Types of Recurrent or Metastatic Head and Metastatic Head and Neck Squamous Cell Carcinoma Aug 26
High number of new directors Aug 22 Bioarctic AB (Publ) Announces Results of Detailed Analysis of the Phase 3 Clarity Ad Study Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s Disease Jul 07
Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee Jun 12
Eisai Submitts Market Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease Filed in South Korea Jun 08
Eisai Submits Marketing Authorisation Application (MAA) for Lecanemab, an Investigational Anti-Amyloid Beta (Aß) Protofibril Antibody May 22 Eisai Co., Ltd. and Biogen Inc. Announce Health Canada Accepts New Drug Submission for Lecanemab May 19
Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024
Eisai Co., Ltd., Annual General Meeting, Jun 21, 2023 May 16
Third quarter 2023 earnings released: EPS: JP¥30.09 (vs JP¥49.43 in 3Q 2022) Feb 08
High number of new directors Jan 30
Eisai Co., Ltd. and Biogen Inc. Announce Lecanemab Receives Priority Review Status in Japan Jan 30 Eisai Accepts Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease
Eisai Co., Ltd. Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer's Disease in Japan Jan 17 Eisai Co., Ltd. and Biogen Inc. Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer's Disease in Europe Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
Eisai Initiates BLA Submission of Data for Lecanemab in China Dec 23
Eisai Presents Results of Lecanemab Phase 3 Confirmatory Clarity AD Study for Early Alzheimer's Disease at CTAD Conference Dec 02
Eisai to Present Latest Data on Fycompa (Perampanel) CIII at the 76th American Epilepsy Society (AES) Annual Meeting Nov 24
High number of new directors Nov 16
Second quarter 2023 earnings released: EPS: JP¥12.44 (vs JP¥14.04 in 2Q 2022) Nov 08
DKSH Holding AG (SWX:DKSH) signed an agreement to acquire Two pharma brands of Eisai. Nov 08 Eisai Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023
Eisai Announces Real-World Evidence on the Clinical Effectiveness of LENVIMA® (lenvatinib) Monotherapy for the Treatment of Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Oct 22
Eisai Co. and Biogen Announce Positive Topline Results from Eisai's Large Global Phase 3 Confirmatory Clarity AD Clinical Trial of Lecanemab Sep 28
Upcoming dividend of JP¥80.00 per share Sep 22
Merck and Eisai Present Results From Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma Sep 11
Eisai Presents New Data from Its Oncology Portfolio and Pipeline At ESMO Congress 2022 Sep 07 Shareholder Returns 4523 N MX Pharmaceuticals MX Market 7D 0% 1.2% 0.4% 1Y n/a -27.0% -11.1%
See full shareholder returns
Return vs Market: Insufficient data to determine how 4523 N performed against the MX Market .
Price Volatility Is 4523 N's price volatile compared to industry and market? 4523 N volatility 4523 N Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 6.4% Market Average Movement 4.0% 10% most volatile stocks in MX Market 6.2% 10% least volatile stocks in MX Market 2.7%
Stable Share Price: 4523 N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 4523 N's volatility change over the past year.
About the Company Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2.
Show more Eisai Co., Ltd. Fundamentals Summary How do Eisai's earnings and revenue compare to its market cap? 4523 N fundamental statistics Market cap Mex$218.90b Earnings (TTM ) Mex$5.18b Revenue (TTM ) Mex$85.55b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 4523 N income statement (TTM ) Revenue JP¥749.46b Cost of Revenue JP¥157.73b Gross Profit JP¥591.73b Other Expenses JP¥546.31b Earnings JP¥45.42b
Last Reported Earnings
Dec 31, 2023
Earnings per share (EPS) 158.37 Gross Margin 78.95% Net Profit Margin 6.06% Debt/Equity Ratio 19.7%
How did 4523 N perform over the long term?
See historical performance and comparison Dividends
2.4% Current Dividend Yield When do you need to buy 4523 N by to receive an upcoming dividend? Eisai dividend dates Ex Dividend Date Mar 28 2024 Dividend Pay Date Jul 01 2024 Days until Ex dividend 287 days Days until Dividend pay date 192 days
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/02/14 01:14 End of Day Share Price 2023/11/17 00:00 Earnings 2023/12/31 Annual Earnings 2023/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Eisai Co., Ltd. is covered by 27 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Atsushi Seki Barclays Koichi Mamegano BofA Global Research Aaron Ho CFRA Equity Research
Show 24 more analysts 